March 15, 2024
We’ve updated our shortage-drug/GLP-1 compounding statement
This week, we updated our statement on rules governing compounding, what FDA guidance says about permissibility of compounding “essentially a copy” of an FDA-approved drug – and what those have to do with GLP-1s.
The revised statement provides additional information on the difference between legitimate compounding and illegal online sales, context related to adverse events attributed to compounded GLP-1s, and further elaboration on lawsuits filed by drug manufacturers against compounding pharmacies.
